Substance Use & Substance Use Disorders (SUD)

Contingency management (CM) is an evidence-based psychosocial therapy for the treatment of stimulant use disorder, as well as a variety of other substance use disorders (SUDs), that is supported by three decades of research. Despite CM’s great potential and demonstrated effectiveness in improving the health and well-being of many people with SUDs, this proven treatment remains underutilized.

Team-based behavioral health care can effectively address clinical needs and mitigate behavioral health workforce shortages. Despite the demonstrated benefits of team-based care models, experts in the fields of behavioral health workforce and network adequacy have noted that existing reimbursement models do not adequately support team-based care.

Using a national Medicaid claims database, this brief estimates the number of pregnant beneficiaries with substance use disorder who lost Medicaid coverage 60 days postpartum at the national and state-level.

In April 2021 the U.S. Department of Health and Human Services (HHS) issued revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder (Practice Guideline).

In this brief, we highlight experiences and practices from substance use treatment providers and their human services partners when serving people of color. We selected providers that focused on serving people of color, and this study was not intended to assess outcomes or effectiveness of any of the practices highlighted.

This updated 2022 vignette provides examples of how a range of Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) cross-agency projects are working to address the opioid overdose crisis by 1) Improving Timeliness and Quality of Outcomes Data 2) Building Capacity for Collection of Patient-Reported Outcomes 3) Building Linkages to Address Co-Morbidities

This brief presents estimates of the number and percentage of children whose parents engage in problematic substance use, including past-year substance use and SUD by substance type and child demographics. Key findings include:

Per Section 223(d)(7)(A) of the Protecting Access to Medicare Act (PAMA) of 2014 (Public Law 113-93), the HHS Secretary must submit to Congress an annual report on the use of funds provided under all demonstration programs conducted under this subsection, not later than one year after the date on which the first state is selected for a demonstration program under this subsection, and annually t

The COVID-19 pandemic had wide-ranging impacts on health care delivery, particularly services that require in-person interactions. For patients needing access to medications to treat pain or certain substance use disorders, the COVID-19 pandemic presented particular challenges for continuity of treatment.

To identify and address gaps in substance use disorder (SUD) treatment capacity, state and federal policymakers need information on the need and demand for different SUD levels of care. To develop this information, this project fielded a survey of Single State Agencies for Substance Use Services and Medicaid agencies to every state and the District of Columbia.